Hadasit Bio-Holdings

Press Releases

Hadasit Bio-Holdings facilitates foreign investment in the traded stock (TASE:HDST)

Dec. 26, 2010

Hadasit Bio Holdings (HBL) operates under a unique business model that combines the Hadassah hospital as a source of world class innovation (intellectual property) and facilities, with the management expertise, funding and liquidity associated with a public listing.

With this vehicle, private and institutional investors can participate in the creation of value based on these unique assets. To date, over $30 M have been raised, 8 companies have been funded and 4 compounds are in the midst of clinical trials, some with the backing of large multinationals.

The HBL business model along with the medical excellence and cutting edge research that emerges from the Hadassah medical centers has attracted great interest around the world, including institutional as well as private investors.

We are happy to provide an easy and convenient investment channel for our international investors:

Shares of HBL (TASE: HDST) can be purchased on the Tel Aviv Stock Exchange (Security No.; 1095405). If you need assistance in executing the trade, please contact the private banking and brokerage services of Bank Leumi USA – a wholly owned subsidiary of Bank Leumi Ltd. – Israel’s leading commercial bank.

Bank Leumi USA has offices in New York, California, Florida and Illinois and the Israeli entity is one of the founders and main members of the Tel Aviv Stock Exchange.

Please address our contact at Bank Leumi (USA) for further assistance in executing trades in HBL stock:

Steven Schieffelin, Senior Vice President, Leumi Investment Services, Inc.

579 Fifth Avenue, NY NY 10017

Steven.Schieffelin@leumiusa.com

 
 

Press Releases Archive